Data from the in vitro study further suggested that the efficacy of DR17 treatment resulted, in part, from the targeting of multiple prostate cancer relevant signaling pathways including PI3K/AKT/mTOR and HSP90/HSP70/AR. Here, MTOR is linked to prostate carcinoma.